La Jolla Pharmaceutical — Investor Presentation (January 2016)
33 slides from La Jolla Pharmaceutical's investor presentation, Jan 11, 2016
Slide 1: Corporate Presentation January 2016
January 2016 Developing Innovative Therapies for Patients Suffering from Life-threatening Diseases NASDAQ: LJPC Corporate Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp
Slide 3: Agenda
• Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Hepcidin) for Iron Overload • LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders • Financial Position Agenda 3
Slide 4: Mission Statement
Mission Statement La Jolla is dedicated to improving the lives of patients suffering from life- threatening diseases by discovering and developing innovative therapies 4
Slide 5: LJPC Corporate Highlights
LJPC Corporate Highlights • Focused on de-risked product opportunities Naturally occurring peptides with well-understood biological functions Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH) Phase 3 registration study actively e
Slide 6: Product Pipeline
Product Pipeline Underway Completed Planned 6 LJPC-501 Angiotensin II LJPC-401 Hepcidin Other R&D Indication IND Phase 1 Phase 2 Phase 3 CRH Q1 2016 Various Q4 2016 HH, Thalassemia, SCD and MDS Q4 2015 LJPC-30Sa & LJPC-30Sb Gentamicin Derivatives Bacterial Infections Rare Genetic Disorders Q1 2015 S
Slide 7: Agenda
• Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Hepcidin) for Iron Overload • LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders • Financial Position Agenda 7
Slide 8: LJPC-501: Overview
LJPC-501: Overview 8 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to current
Slide 9: Three Systems Work in Harmony to Regulate Blood Pressure
Three Systems Work in Harmony to Regulate Blood Pressure 9 Current therapeutic options for the treatment of acute hypotension only leverage the adrenal system and vasopressin system The Body’s Three Systems that Regulate Blood Pressure
Slide 10: High Doses of Catecholamines Increase Mortality
High Doses of Catecholamines Increase Mortality 10 1Sviri et al, J. of Crit Care, 29;157-160, 2014 • Catecholamines (i.e., norepinephrine, epinephrine and dopamine) cause cardiac toxicity, digital necrosis and metabolic complications leading to higher mortality1 • Blocking the cardiac toxicity of no
Slide 11: Norepinephrine Dose Decreases with Angiotensin II
Norepinephrine Dose Decreases with Angiotensin II Surrogate Effect on Blood Pressure 11 Source: Chawla et al, Critical Care, 18:534, 2014 • Randomized, placebo-controlled, double-blind pilot trial • Primary efficacy endpoint: Catecholamine dose sparing; surrogate for BP effect • Published October 20
Slide 12: LJPC-501: Phase 3 Trial in CRH
LJPC-501: Phase 3 Trial in CRH SPA Agreement with FDA Reached, Trial Enrolling 12 • ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 trial initiated in March 2015 • Randomized, placebo-controlled, double-blind Phase 3 trial • Patient population: catecholamine-resistant, based on amoun
Slide 13: LJPC-501: Large Population in Need
LJPC-501: Large Population in Need 13 *Catecholamine-resistant hypotension is defined as requiring a norepinephrine-equivalent dose >20mg/day Sources: IMS Health data; DRG physician interviews, 2014-2015; AHA hospital statistics, 2014; Angus et al, 2001; Kumar et al, 2011; Annane et al, 2002 Total A
Slide 14: LJPC-501: Attractive Pricing Potential
LJPC-501: Attractive Pricing Potential 14 Prices of Hospital-Based Drugs Reimbursed under DRGs Source: Wolters Kluwer PriceRx Pro, product package inserts, IMS Health inpatient/outpatient hospital charge master Catecholamine-Resistant* Catecholamine-Responsive Average total cost per patient $60,668
Slide 15: LJPC-501: Market Survey
LJPC-501: Market Survey Strong Interest Even among P&T Decision Makers 15 Robust (N=100) survey of physicians, 50% of which are P&T decision makers, shows strong interest based on evidence in primary endpoint alone Source: IMS Health survey, 2015 Endpoints Achieved Scenario 1 Scenario 2 Scenario 3 I
Slide 16: Summary of LJPC-501
Summary of LJPC-501 16 • LJPC-501 is a proprietary formulation of angiotensin II, a naturally occurring regulator of blood pressure • Catecholamine-resistant hypotension (CRH) is an acute, life-threatening condition in which blood pressure drops to dangerously low levels and is unresponsive to curre
Slide 17: Agenda
• Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Hepcidin) for Iron Overload • LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders • Financial Position Agenda 17
Slide 18: LJPC-401: Overview
LJPC-401: Overview • LJPC-401 is a novel formulation of hepcidin, a naturally occurring regulator of iron absorption and distribution • Hereditary hemochromatosis (HH) is a disease characterized by a deficiency of hepcidin that results in excessive iron accumulation, which is toxic to vital organs s
Slide 19: Hepcidin: The Insulin of Iron Metabolism
Hepcidin: The Insulin of Iron Metabolism • Hepcidin: the insulin of iron metabolism Regulates iron absorption and disposition in all organs Rapid and sustained lowering of iron levels • Progress SQ formulation developed Orphan Drug Designation granted (EU) Phase 1 ongoing 19 GLP Toxicology Study in
Slide 20: LJPC-401: Phase 1 Trial Design
LJPC-401: Phase 1 Trial Design • Population: Adult patients with refractory or hemolytic anemia of any type, or HH • Design: Phase 1, open- label, dose-escalation, PK/PD/IM study • Iron studies: • Serum iron, ferritin, transferrin • TIBC, UIBC • Non-transferrin bound iron Escalating dose cohorts 3 t
Slide 21: LJPC-401: Phase 1 Preliminary Data
LJPC-401: Phase 1 Preliminary Data • 6 patients enrolled and treated • 2 dose cohorts 1 mg and 5 mg • No treatment emergent adverse events identified as dose limiting • No adverse clinical lab changes noted • Serum iron data available 21
Slide 22: LJPC-401: Effect on Serum Iron
-35% -30% -25% -20% -15% -10% -5% 0% BASELINE/D1 DAY 1: 2HRS DAY 1: 4HRS DAY 1: 8 HRS D2: 24 HRS S er um Ir on % C ha ng e Time Point v LJPC-401: Phase 1 Preliminary Data Effect on Serum Iron 22 Baseline Day 1 Day 1 2 Hrs Day 1 4 Hrs Day 1 8 Hrs Day 2 24 Hrs Time Point Cohort 1 (1 mg) Cohort 2 (5 mg
Slide 23: LJPC-401: Patient Need
LJPC-401: Patient Need • Hereditary Hemochromatosis (HH) Most common genetic disease in Caucasians Silent Killer - Iron accumulation can lead to liver cirrhosis, liver cancer, heart disease and/or failure, dementia and diabetes No FDA-approved treatment Current treatments don’t address the underlyin
Slide 24: Agenda
• Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Hepcidin) for Iron Overload • LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders • Financial Position Agenda 24
Slide 25: LJPC-30Sa/b: Overview
LJPC-30Sa/b: Overview • LJPC-30Sa and LJPC-30Sb are purified derivatives of gentamicin, which retain biologic activity but lack traditional kidney toxicity • Gentamicin: FDA-approved, standard-of-care for serious Gram-negative bacterial infections Mixture of several distinct but closely related chem
Slide 26: LJPC-30Sa/b: Potential for Improved Clinical Profile
Next-generation improved gentamicin derivative 1. Retain activity LJPC-30Sa/b: Potential for Improved Clinical Profile 26 2. Improve safety 0.0 4.0 8.0 12.0 16.0 placebo next-generation gentamicin derivative gentamicin In hi bi tio n/ ki ll zo ne (m m ) B.subtilus K.pneumonieae (kill) K.pneumonieae
Slide 27: LJPC-30Sa/b: Mechanism of Action
Gentamicin induces errors in the translation of genes into proteins Bacteria LJPC-30Sa/b: Mechanism of Action Can Be Leveraged Down Two Development Paths 27 Alters protein synthesis leading to cell death Alters protein synthesis to allow read through of stop-codon mutations Humans
Slide 28: LJPC-30Sa/b: Current Antibiotic Usage
LJPC-30Sa/b: Current Antibiotic Usage • Antibiotic opportunity = $500+ million per year in U.S. Market could expand with a safer alternative – Increased duration of therapy, increased penetration, and/or new indications • Other large potential market opportunity in rare genetic disorders, such as cy
Slide 29: LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis
LJPC-30Sa/b: Clinical Proof-of-Concept in Cystic Fibrosis 29 References: Sermet-Gaudelus et al, BMC Medicine, 5:5, 2007; Wilchanski et al, NEJM, 349:1433-41, 2003; Clancy J.P. et al, Am J Respir Crit Care Med, 163:1683-1692, 2001 • Three, independent studies suggest gentamicin helps read through sto
Slide 30: Agenda
• Overview of LJPC • LJPC-501 (Angiotensin II) for CRH • LJPC-401 (Hepcidin) for Iron Overload • LJPC-30Sa/b (Gentamicin Derivatives) for Bacterial Infections and Rare Genetic Disorders • Financial Position Agenda 30
Slide 31: Financial Position
Financial Position 31 Condensed Balance Sheet Data As of September 30, 2015 (in millions) Cash $135.1 Total liabilities $4.3 Total shareholders’ equity $133.6 Fully Diluted, As-Converted Shares Outstanding* 27,304,103 *Includes common stock, preferred stock (as-converted) & outstanding equity awards
Slide 32: LJPC Corporate Highlights
LJPC Corporate Highlights • Focused on de-risked product opportunities Naturally occurring peptides with well-understood biological functions Derivative components of FDA-approved products • LJPC-501 (angiotensin II) for catecholamine-resistant hypotension (CRH) Phase 3 registration study actively e
Slide 33: hie
hie \) La Jolla Pharmaceutical
LA Jolla Pharmaceutical — Investor Presentation (January 2016) on 6ix